First American Bank acquired a new stake in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 32,200 shares of the biopharmaceutical company’s stock, valued at approximately $281,000. First American Bank owned approximately 0.06% of Regulus Therapeutics as of its most recent SEC filing.

Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) traded up 2.23% during trading on Friday, hitting $5.51. The stock had a trading volume of 192,048 shares. The firm has a 50 day moving average price of $7.78 and a 200-day moving average price of $8.14. Regulus Therapeutics Inc has a 52 week low of $5.23 and a 52 week high of $21.22. The stock’s market capitalization is $288.40 million.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.12. On average, equities research analysts forecast that Regulus Therapeutics Inc will post ($1.19) EPS for the current fiscal year.

A number of equities analysts have issued reports on RGLS shares. Wedbush restated a “buy” rating and set a $39.00 price target (up from $23.00) on shares of Regulus Therapeutics in a report on Monday, November 2nd. Needham & Company LLC restated a “buy” rating and set a $25.00 price target on shares of Regulus Therapeutics in a report on Thursday, November 5th. Wells Fargo started coverage on Regulus Therapeutics in a report on Thursday, December 3rd. They set an “outperform” rating on the stock. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “strong-buy” rating and set a $11.00 price target on the stock in a report on Tuesday, November 10th. Finally, FBR & Co. restated an “outperform” rating and set a $30.00 price target on shares of Regulus Therapeutics in a report on Tuesday, November 3rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Regulus Therapeutics currently has an average rating of “Buy” and an average price target of $26.71.

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Its development programs include microRNA target miR-122, miR-21, RG-012, miR-103/107, miR-19, miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs, RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.

12 Month Chart for NASDAQ:RGLS

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Regulus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.